ivermectin in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Krolewiecki, 2020 0.49 [0.01; 26.05]
Shahbaznejad, 2020 2.21 [0.07; 67.87]
1.16 [0.09 ; 15.55 ] Krolewiecki, 2020, Shahbaznejad, 2020 2 0% 118 moderate not evaluable deathsdetailed results Hashim A, 2020 0.48 [0.11; 1.99]
Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
0.40 [0.12 ; 1.36 ] Hashim A, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 3 0% 548 moderate not evaluable clinical deteriorationdetailed results Hashim A, 2020 0.40 [0.10; 1.63]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
0.44 [0.24 ; 0.78 ] Hashim A, 2020, NCT04523831 (Mahmud), 2020 2 0% 503 moderate not evaluable clinical improvementdetailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable clinical improvement (7-day)detailed results NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
1.93 [1.27 ; 2.93 ] NCT04523831 (Mahmud), 2020 1 0% 363 NA not evaluable clinical improvement (time to event analysis only)detailed results NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
1.89 [1.06 ; 3.38 ] NCT04523831 (Mahmud), 2020 1 0% 400 NA not evaluable mechanical ventilationdetailed results Shahbaznejad, 2020 2.24 [0.19; 25.88]
2.24 [0.19 ; 25.88 ] Shahbaznejad, 2020 1 0% 73 NA not evaluable serious adverse eventsdetailed results Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
2.14 [0.21 ; 21.56 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 2 0% 408 moderate not evaluable adverse eventsdetailed results Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
3.80 [0.36 ; 40.08 ] Krolewiecki, 2020, NCT04523831 (Mahmud), 2020 2 59% 408 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 06:37 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 684,886
- roots T: 290